Davis Polk advised the underwriters in the initial public offering of RemeGen Co., Ltd. on the Hong Kong Stock Exchange and an international offering and listing in reliance on Rule 144A and Regulation S. The gross proceeds from the offering amounted to approximately HK$4 billion (US$514.3 million) prior to any exercise of the over-allotment option.

RemeGen Co., Ltd. is a commercial-ready biopharmaceutical company based in China, committed to the discovery, development and commercialization of innovative and differentiated biologics for the treatment of autoimmune, oncology and ophthalmic diseases with unmet medical needs in China and globally. Since its inception in 2008, it has discovered and developed a robust pipeline of more than ten drug candidates. Among its drug candidates, five are in clinical development stage targeting 17 indications and more than five have filed the investigational new drug (IND) application or are in IND filing preparation stage. It expects to receive approval from the NMPA to market two of its core drug candidates, telitacicept for SLE (RC18) and disitamab vedotin (RC48) for GC in China in the fourth quarter of 2020 and the second quarter of 2021, respectively.

The Davis Polk corporate team included partners Yang Chu and Li He, counsel Xuelin (Steve) Wang, associates Lillian Lian and Cathy Yuen and registered foreign lawyers Jennifer (Yujia) Jiang, Lulu Han and Allie Ma. Associate Omer Harel provided tax advice. Members of the Davis Polk team are based in the Hong Kong and London offices.

Copy link to share post